Ambit Biosciences (NASDAQ: AMBI) and Abattis Bioceuticals (CNSX: ATT) Lead the Top Sector Gainers

Ambit Biosciences Corp (NASDAQ: AMBI) and Abattis Bioceuticals Corp (CNSX: ATT), lead the top small cap stock gainers for various sectors on both sides the border, including one that saw its share price soar of 87%.

Top U.S. Gainer

Ambit Biosciences Corp (NASDAQ: AMBI), engaged in discovering, developing small molecule and orally administered enzyme inhibitors for the treatment of acute myeloid leukemia and inflammatory diseases, was the top performer in the U.S. healthcare sector, breaking its key technical resistance level of 200-Day DMA at $8.21 after skyrocketing 87.0%, Monday and closed at $15.34, while recording significant trading volumes of 3.0 million shares. Recently, the company announced that it is being acquired by Japanese drugmaker Daiichi Sankyo Co Ltd in a deal valued up to $410 million, wherein Ambit shareholders are being offered $15.00 in cash plus the right to receive a payment of as much as $4.50 per share if certain milestones are achieved. During the past 5-trading sessions, AMBI gained 87.0% with daily average trading volumes of 627,602 shares, while the stock accumulated over 102.6% during the past one month with daily average trading volumes of 152,337 shares. The stock is 59.1% year-to-date.

1-Year Price Chart

Top Canadian Gainer

Abattis Bioceuticals Corp (CNSX: ATT), engaged in researching, developing and manufacturing natural botanical formulations to prevent and to treat influenza strains in birds, humans and other mammals, was the top sector gainer, after climbing 23.4% and closed at C$0.40 Monday, while recording significant trading volumes of 474,407 shares. During the past 5-trading sessions, ATT gained 29.5% with daily average trading volumes of 295,078 shares, while the stock tumbled down by 18.6% during the past one month with daily average trading volumes of 219,934 shares. The stock is 1875% year-to-date.

1-Year Price Chart